Portfolio overview
Discover our portfolio.
Yes to value creation in generics.
Farmaprojects’ portfolio embodies our commitment to offer a comprehensive and balanced product range with value creation at its core.
We create value for you at all levels, from highly competitive standard oral solids generics to innovative value-added products. Our broad range of medicines covers most therapeutic areas and a diverse range of dosage forms at different development stages. Discover our specialized products such as complex respiratory DPI, innovative cardio combinations and oligonucleotides.
Our value creation goes beyond the product itself. We believe that defining new ways of partnering paves the way for new opportunities in the B2B industry. We offer flexible business models to our clients and partners, from out-licensing to co-developments and distribution. Say yes to value creation in generics!
Product list
Download our product lists or browse through our interactive product list
General product list
Ophthalmics product list
Balanced portfolio
Reach the peak of value creation through our balanced portfolio.
Through our 5 R&D centers employing more than 370 specialized professionals, we develop from standard generics to innovative products. Due to our vast experience in complex products, we also take on challenging molecules and internalize new state-of-the-art technologies to develop value-added products.
At Farmaprojects our ambition is to offer a comprehensive and balanced portfolio targeting the needs of different customer profiles, from local champions to multinational generic leaders.
Through Polpharma’s large R&D and industrial scale manufacturing capabilities, we provide you with competitive timelines and cost for standard generics.
Through our 5 R&D centers employing more than 370 specialized professionals, we develop from standard generics to innovative products. Due to our vast experience in complex products, we also take on challenging molecules and internalize new state-of-the-art technologies to develop value-added products.
Standard & High-Volume Generics
- Factor Xa inhibitors
- SGLT-2 inhibitors
- S1P modulators
- JAK-1 inhibitors
Early Launch Opportunities / Markets
- Design-around strategies
- Early market opportunities & timelines
- First-to-market & first-to-file ambition
Differentiated Generics
- Preservative-free & multidose ophthalmic products
- Innovative fixed dose combinations in cardio
Complex Generics
- Respiratory delivery
- RNA therapeutics (siRNA, asRNA)
- Complex injectables
Value Added Products
- Innovation in device design, administration form and posology for a better patient experience and compliance
- Investment in repurposing to find safe and effective molecules to reach more patients
- Innovation in patient-centric drug delivery technologies/formulations
Partnership models
Beyond out-licensing.
Shaping the future of B2B together with you.
- Flexible business models
- Co-development opportunities
- Early licensing